President Donald Trump signed an order Tuesday aimed at tightening restrictions on direct-to-consumer drug advertising, expanding his administration’s scrutiny against big pharmaceutical companies and their business practices.
Trump's Executive Order Targets Deceptive Pharmaceutical Advertising: Increased Transparency & Stronger FDA Enforcement. The order, signed Tuesday, aims to curb misleading drug ads, demanding greater disclosure of risks and stricter FDA oversight. Health Secretary Robert F. Kennedy Jr. will spearhead efforts to ensure accuracy in advertising, while the FDA issues cease-and-desist letters and warnings to pharmaceutical companies. This action follows Trump's ongoing campaign to lower drug prices and increase accountability within the industry
President Trump's Executive Order Targets Deceptive Prescription Drug Advertising: The FDA, under Commissioner Marty Makary, will strengthen enforcement of advertising regulations to ensure truthful and non-misleading direct-to-consumer prescription drug ads. This action combats misleading pharmaceutical marketing and protects consumers
FDA Crackdown on Deceptive Pharmaceutical Ads: Thousands of Warning Letters Issued, 100 Cease-and-Desist Orders Served. Following President Trump's executive order targeting misleading drug advertising, the FDA is taking action against pharmaceutical companies with deceptive marketing campaigns
Trump Administration Issues Hundreds of Cease-and-Desist Letters to Pharma Companies for Deceptive Ads, Targeting Super Bowl Weight Loss Drug Ad as Example. The FDA's crackdown on misleading pharmaceutical advertising includes thousands of warning letters and over 100 cease-and-desist orders
FTC cracks down on pharmaceutical advertising: Social media influencers and companies promoting drugs without proper disclosure face federal scrutiny, according to CNBC sources. The crackdown targets deceptive ads and aims to increase transparency in direct-to-consumer drug marketing
Stay informed on breaking news! Sign up for Forbes text alerts and receive instant updates on the day's top stories. Text "Alerts" to (201) 335-0739 or register here
Trump's new executive order cracks down on misleading pharmaceutical advertising, demanding greater transparency and accuracy in drug ads. While Kennedy previously advocated for a complete TV advertising ban, this latest action focuses on stricter enforcement of existing regulations and increased scrutiny of deceptive marketing practices by pharmaceutical companies and social media influencers
Trump's Executive Order Targets Big Pharma: Price Cuts & Advertising Crackdown. Facing pressure to lower prescription drug costs, President Trump demanded price reductions from AbbVie, Eli Lilly, Pfizer, Novo Nordisk, and other pharmaceutical giants by September. This action supports his "most-favored-nation" policy, aiming to align US drug prices with the lowest prices in other developed countries. The order also cracks down on misleading direct-to-consumer drug advertising
Trump Demands Immediate Pharmaceutical Price Cuts: New FDA Crackdown on Drug Ads & Misleading Marketing
Source: Original Article